Clinical Trials · NCT04003519

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

Name: Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

WithdrawnN/ALanreotide

Phase: N/A
Recruitment status: Withdrawn
Sponsor: Ipsen
Enrollment: 0
Start date: Apr 2020
Locations: See registry
Primary endpoint: Proportion of subjects with normalization of centrally assessed age and sex adjusted IGF-I levels at visit 4 (about 12 months) after treatment start with lanreotide autogel.

View Lanreotide compound reference